{"id":"capecitabine-tablets","safety":{"commonSideEffects":[{"rate":"60","effect":"Hand-foot skin reaction (palmar-plantar erythrodysesthesia)"},{"rate":"55","effect":"Diarrhea"},{"rate":"35","effect":"Nausea"},{"rate":"25","effect":"Vomiting"},{"rate":"25","effect":"Stomatitis"},{"rate":"40","effect":"Fatigue"},{"rate":"25","effect":"Neutropenia"},{"rate":"5","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":{"setId":"87173e7c-6e29-2e85-e053-2a91aa0ae4ae","title":"CAPECITABINE TABLETS, 150 MG TABLET CAPECITABINE TABLETS, 500 MG TABLET [PRODIGY INNOVATION, LLC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Capecitabine is an oral fluoropyrimidine carbamate that undergoes hepatic and tissue-level enzymatic conversion to 5-fluorouracil (5-FU). The active 5-FU metabolite inhibits thymidylate synthase, blocking dTMP synthesis and DNA replication, while also incorporating into RNA to disrupt protein synthesis. This mechanism preferentially affects rapidly dividing cancer cells.","oneSentence":"Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:55.083Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic breast cancer"},{"name":"Gastric cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT06312176","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-14","conditions":"Breast Neoplasms","enrollment":1200},{"nctId":"NCT07060807","phase":"PHASE3","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-21","conditions":"Breast Neoplasms","enrollment":1000},{"nctId":"NCT05629585","phase":"PHASE3","title":"A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-11-28","conditions":"Breast Cancer","enrollment":1174},{"nctId":"NCT06469944","phase":"PHASE1, PHASE2","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-20","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":160},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT07331155","phase":"PHASE2","title":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2026-02-26","conditions":"Advanced Solid Tumour","enrollment":110},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT05568095","phase":"PHASE3","title":"A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2022-11-21","conditions":"Advanced Upper Gastrointestinal Tract Adenocarcinoma","enrollment":1040},{"nctId":"NCT04494425","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-24","conditions":"Advanced or Metastatic Breast Cancer","enrollment":866},{"nctId":"NCT06099769","phase":"PHASE2","title":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-10-18","conditions":"Metastatic Breast Cancer","enrollment":201},{"nctId":"NCT02000622","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-03-27","conditions":"Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation","enrollment":302},{"nctId":"NCT05985655","phase":"PHASE1, PHASE2","title":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.","startDate":"2023-07-06","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC)","enrollment":230},{"nctId":"NCT07118527","phase":"PHASE3","title":"A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-08-18","conditions":"Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":600},{"nctId":"NCT07390383","phase":"PHASE2","title":"A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2026-03-25","conditions":"Advanced Solid Tumour","enrollment":110},{"nctId":"NCT05412082","phase":"PHASE1","title":"SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2022-10-05","conditions":"Locally Advanced Rectal Cancer","enrollment":25},{"nctId":"NCT05126719","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Miracogen Inc.","startDate":"2023-04-06","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":238},{"nctId":"NCT07385703","phase":"PHASE3","title":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2026-03","conditions":"Adenocarcinoma","enrollment":752},{"nctId":"NCT05104866","phase":"PHASE3","title":"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-18","conditions":"Breast Cancer","enrollment":732},{"nctId":"NCT05062889","phase":"PHASE2","title":"Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients","status":"SUSPENDED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-17","conditions":"Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer","enrollment":477},{"nctId":"NCT05165069","phase":"PHASE3","title":"The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-01-01","conditions":"Hand-foot Syndrome","enrollment":234},{"nctId":"NCT07047365","phase":"PHASE3","title":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-25","conditions":"HER2-positive Advanced Breast Cancer","enrollment":416},{"nctId":"NCT06279364","phase":"PHASE3","title":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2024-02-28","conditions":"Triple Negative Breast Cancer","enrollment":524},{"nctId":"NCT05374512","phase":"PHASE3","title":"A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-05-16","conditions":"Breast Cancer","enrollment":644},{"nctId":"NCT07362264","phase":"PHASE1","title":"A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2025-07-01","conditions":"Liver Cancer","enrollment":50},{"nctId":"NCT07222215","phase":"PHASE2","title":"PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)","status":"RECRUITING","sponsor":"Kristina A. Fanucci","startDate":"2026-01-16","conditions":"Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer","enrollment":297},{"nctId":"NCT05633654","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-12-12","conditions":"Triple Negative Breast Cancer","enrollment":1514},{"nctId":"NCT07347951","phase":"PHASE2","title":"A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-12-01","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":30},{"nctId":"NCT04721977","phase":"PHASE2","title":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-04-08","conditions":"Breast Cancer","enrollment":66},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT07328919","phase":"PHASE3","title":"Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations","status":"NOT_YET_RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma","enrollment":138},{"nctId":"NCT03869892","phase":"PHASE3","title":"Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2019-03-21","conditions":"Metastatic Colorectal Cancer","enrollment":856},{"nctId":"NCT06065371","phase":"PHASE1","title":"Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy","status":"RECRUITING","sponsor":"Henry Ford Health System","startDate":"2024-11-20","conditions":"Gastrointestinal Cancer","enrollment":20},{"nctId":"NCT06112379","phase":"PHASE3","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-14","conditions":"Breast Cancer","enrollment":1902},{"nctId":"NCT05472948","phase":"PHASE2","title":"Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-02-01","conditions":"Adenocarcinoma of Small Intestine, Appendix Carcinoma, Metastatic","enrollment":36},{"nctId":"NCT05322577","phase":"PHASE1, PHASE2","title":"A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-05-17","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":72},{"nctId":"NCT04428151","phase":"PHASE2","title":"Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":408},{"nctId":"NCT06703177","phase":"PHASE1, PHASE2","title":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-02-18","conditions":"Advanced Solid Tumors","enrollment":876},{"nctId":"NCT05800275","phase":"PHASE2","title":"Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2023-12-18","conditions":"Leptomeningeal Metastasis, Leptomeningeal Disease, HER2-positive Metastatic Breast Cancer","enrollment":30},{"nctId":"NCT05973864","phase":"PHASE2","title":"Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-03-11","conditions":"Triple Negative Breast Neoplasms","enrollment":220},{"nctId":"NCT01972919","phase":"PHASE2","title":"MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2015-12-10","conditions":"Unresectable Pancreatic Cancer","enrollment":23},{"nctId":"NCT05980481","phase":"PHASE2, PHASE3","title":"A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-08-04","conditions":"Gastric Cancer","enrollment":201},{"nctId":"NCT04158362","phase":"PHASE3","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-11","conditions":"Cancer Metastatic","enrollment":180},{"nctId":"NCT06079983","phase":"PHASE3","title":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","status":"RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2023-12-01","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT02978612","phase":"PHASE2","title":"Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2016-06","conditions":"Colon Cancer","enrollment":170},{"nctId":"NCT07151872","phase":"PHASE2","title":"Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09","conditions":"CLDN18.2-positive Advanced Biliary Tract Cancer","enrollment":120},{"nctId":"NCT06247956","phase":"PHASE2","title":"Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-03-11","conditions":"Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma","enrollment":153},{"nctId":"NCT05775900","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2023-02-01","conditions":"Metastatic Colorectal Cancer","enrollment":24},{"nctId":"NCT03501979","phase":"PHASE2","title":"Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2019-02-20","conditions":"Metastatic Breast Cancer, Leptomeningeal Disease","enrollment":17},{"nctId":"NCT06255392","phase":"PHASE3","title":"Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer","enrollment":200},{"nctId":"NCT04607421","phase":"PHASE3","title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-21","conditions":"Neoplasms","enrollment":831},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT06208410","phase":"PHASE1, PHASE2","title":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","startDate":"2024-01-11","conditions":"Advanced Solid Tumors","enrollment":306},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT01630083","phase":"PHASE2","title":"Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-07-19","conditions":"CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Gastric Adenocarcinoma","enrollment":252},{"nctId":"NCT04789096","phase":"PHASE2","title":"Tucatinib Together With Pembrolizumab and Trastuzumab","status":"TERMINATED","sponsor":"Breast Cancer Trials, Australia and New Zealand","startDate":"2023-03-07","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":31},{"nctId":"NCT06622057","phase":"PHASE3","title":"D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"InnoPharmax Inc.","startDate":"2025-07-01","conditions":"Biliary Tract Cancer (BTC)","enrollment":195},{"nctId":"NCT06942767","phase":"PHASE2","title":"Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-06","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":100},{"nctId":"NCT04793932","phase":"PHASE3","title":"Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Associazione Italiana per lo Studio del Pancreas","startDate":"2020-11-03","conditions":"Pancreas Ductal Adenocarcinoma","enrollment":261},{"nctId":"NCT06775236","phase":"PHASE1, PHASE2","title":"Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-03-20","conditions":"Advanced Solid Tumors, Breast Cancer","enrollment":410},{"nctId":"NCT01924819","phase":"PHASE2, PHASE3","title":"Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":574},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT06128252","phase":"NA","title":"Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-09-01","conditions":"Gastric Cancer","enrollment":96},{"nctId":"NCT06759090","phase":"PHASE2","title":"Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2025-01-15","conditions":"Metastatic Pancreatic Carcinoma","enrollment":43},{"nctId":"NCT03563157","phase":"PHASE1, PHASE2","title":"QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-09-28","conditions":"Colorectal Cancer Metastatic, mCRC","enrollment":2},{"nctId":"NCT06722950","phase":"PHASE2","title":"Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2024-12","conditions":"Colorectal Adenoma","enrollment":120},{"nctId":"NCT06143553","phase":"PHASE3","title":"Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Yizhong Pharmaceutical Co., Ltd.","startDate":"2023-09-25","conditions":"Metastatic Breast Cancer (MBC)","enrollment":168},{"nctId":"NCT03228043","phase":"NA","title":"Apatinib for Resectable Colorectal Cancer","status":"WITHDRAWN","sponsor":"Nanchong Central Hospital","startDate":"2020-03-01","conditions":"Apatinib, Outcome, Fatal, Colorectal Cancer","enrollment":""},{"nctId":"NCT02199236","phase":"PHASE1","title":"Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-07","conditions":"Rectal or Anal Cancer","enrollment":15},{"nctId":"NCT06656624","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-13","conditions":"Advanced Breast Cancer","enrollment":190},{"nctId":"NCT03839823","phase":"PHASE2","title":"Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-02-25","conditions":"Breast Cancer","enrollment":222},{"nctId":"NCT03872388","phase":"PHASE2","title":"Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-09-23","conditions":"Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8","enrollment":6},{"nctId":"NCT04488159","phase":"PHASE3","title":"Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer","status":"WITHDRAWN","sponsor":"Johannes Laengle, MD, PhD","startDate":"2024-12-01","conditions":"Colon Cancer Stage III","enrollment":""},{"nctId":"NCT02743221","phase":"PHASE2","title":"A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2016-04-29","conditions":"Metastatic Colorectal Cancer","enrollment":154},{"nctId":"NCT04464174","phase":"PHASE2","title":"Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-08","conditions":"Triple Negative Breast Cancer","enrollment":54},{"nctId":"NCT06513221","phase":"PHASE2","title":"A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-25","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT06483386","phase":"PHASE2","title":"Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-15","conditions":"Breast Cancer","enrollment":109},{"nctId":"NCT06458413","phase":"PHASE2","title":"Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Min Yan, MD","startDate":"2024-06-05","conditions":"Breast Cancer Recurrent","enrollment":40},{"nctId":"NCT05420779","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations","status":"RECRUITING","sponsor":"Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.","startDate":"2022-06-30","conditions":"Breast Cancer Metastatic","enrollment":125},{"nctId":"NCT04124601","phase":"PHASE2","title":"Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer","status":"COMPLETED","sponsor":"Johannes Laengle, MD, PhD","startDate":"2020-06-01","conditions":"Rectal Cancer","enrollment":80},{"nctId":"NCT06374888","phase":"PHASE2","title":"Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"Convalife (Shanghai) Co., Ltd.","startDate":"2024-04-30","conditions":"Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis","enrollment":28},{"nctId":"NCT06339281","phase":"PHASE2","title":"A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Li Huiping","startDate":"2024-05-01","conditions":"Advanced Breast Cancer","enrollment":68},{"nctId":"NCT06202261","phase":"PHASE1, PHASE2","title":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-04-13","conditions":"Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies","enrollment":154},{"nctId":"NCT03322215","phase":"PHASE2","title":"HR+/HER2- Advanced Breast Cancer and Endocrine Resistance","status":"TERMINATED","sponsor":"Theodoros Foukakis","startDate":"2017-10-24","conditions":"Breast Cancer Metastatic","enrollment":42},{"nctId":"NCT06268327","phase":"PHASE2, PHASE3","title":"Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-04-30","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT06246461","phase":"NA","title":"The Therapeutic Effect of Different Doses of Capecitabine","status":"COMPLETED","sponsor":"Jingjiang People's Hospital","startDate":"2022-01-01","conditions":"Capecitabine","enrollment":150},{"nctId":"NCT06229067","phase":"PHASE2","title":"Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-01-19","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":182},{"nctId":"NCT04400695","phase":"PHASE3","title":"A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2020-09-29","conditions":"Breast Cancer","enrollment":366},{"nctId":"NCT05737563","phase":"PHASE3","title":"PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-02-17","conditions":"Esophageal Squamous Cell Carcinoma Abdominal Stage 0","enrollment":380},{"nctId":"NCT03607656","phase":"PHASE2, PHASE3","title":"The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2018-06-08","conditions":"Gastric Cancer Stage IIIB, Gastric Cancer Stage IIIC","enrollment":270},{"nctId":"NCT05512520","phase":"PHASE2","title":"Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-09-20","conditions":"Metastatic Esophageal Squamous Cell Carcinoma","enrollment":126},{"nctId":"NCT06115733","phase":"NA","title":"Study of Fuquinitinib Combined With Capecitabine First-line Maintenance in the Treatment of Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2023-12-28","conditions":"Colorectal Carcinoma","enrollment":56},{"nctId":"NCT05415917","phase":"PHASE2","title":"Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-07-29","conditions":"Pancreatic Cancer","enrollment":75},{"nctId":"NCT04262804","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC","status":"UNKNOWN","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2020-01-13","conditions":"Breast Cancer Metastatic","enrollment":123},{"nctId":"NCT05845138","phase":"PHASE1, PHASE2","title":"A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.","status":"UNKNOWN","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2023-07-25","conditions":"Breast Cancer","enrollment":116},{"nctId":"NCT02611960","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-04-18","conditions":"Nasopharyngeal Neoplasms","enrollment":233},{"nctId":"NCT05940441","phase":"","title":"A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2023-07-01","conditions":"to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally Advanced Hypopharyngeal Carcinoma","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Capecitabine","Xeloda","Biogaran Capecitabine"],"phase":"marketed","status":"active","brandName":"Capecitabine tablets","genericName":"Capecitabine tablets","companyName":"UNICANCER","companyId":"unicancer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth. Used for Metastatic colorectal cancer, Metastatic breast cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}